Braveheart Bio (NASDAQ:BRVE – Get Free Report) was upgraded by research analysts at Jefferies Financial Group to a “strong-buy” rating in a research note issued on Monday, Zacks reports.
A number of other equities analysts have also recently issued reports on BRVE. TD Cowen initiated coverage on Braveheart Bio in a report on Monday. They issued a “buy” rating on the stock. The Goldman Sachs Group began coverage on Braveheart Bio in a report on Monday. They set a “buy” rating and a $48.00 target price for the company. Wall Street Zen upgraded Braveheart Bio to a “hold” rating in a research report on Saturday, August 15th. Stifel Nicolaus started coverage on Braveheart Bio in a research note on Monday. They issued a “buy” rating and a $45.00 price target on the stock. Finally, Cantor Fitzgerald began coverage on Braveheart Bio in a report on Monday. They set an “overweight” rating and a $40.00 price objective on the stock. Two analysts have rated the stock with a Strong Buy rating and three have given a Buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $45.25.
Check Out Our Latest Research Report on Braveheart Bio
Braveheart Bio Trading Down 7.1%
Insider Activity
In other news, Director Orbimed Advisors Llc bought 1,940,000 shares of the business’s stock in a transaction on Friday, August 7th. The shares were bought at an average cost of $18.00 per share, with a total value of $34,920,000.00. Following the purchase, the director directly owned 11,901,826 shares in the company, valued at $214,232,868. This trade represents a 19.47% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Christopher Viehbacher bought 83,333 shares of Braveheart Bio stock in a transaction dated Friday, August 7th. The stock was acquired at an average price of $18.00 per share, with a total value of $1,499,994.00. Following the acquisition, the director directly owned 609,519 shares of the company’s stock, valued at approximately $10,971,342. This represents a 15.84% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders bought 8,751,942 shares of company stock worth $157,534,956.
About Braveheart Bio
We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.
Read More
- Five stocks we like better than Braveheart Bio
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
- Insiders Are Betting Big on These 3 Healthcare Stocks
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Receive News & Ratings for Braveheart Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Braveheart Bio and related companies with MarketBeat.com's FREE daily email newsletter.
